Cancer Statistics, 2006

  title={Cancer Statistics, 2006},
  author={Ahmedin Jemal and Rebecca L. Siegel and Elizabeth E. Ward and Taylor Murray and Jiaquan Xu and Carol Smigal and Michael J. Thun},
  journal={CA: A Cancer Journal for Clinicians},
Each year, the American Cancer Society estimates the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute and mortality data from the National Center for Health Statistics. Incidence and death rates are age‐standardized to the 2000 US standard million population. A total of 1,399,790 new cancer cases and 564,830 deaths from… 
Targeted therapy in metastatic colon cancer.
The pattern of changes in the management of metastatic colorectal cancer, the long-term outcomes and the associated cost are discussed.
Prostate Cancer Epidemiology
The incidence of prostate cancer spiked in the United States in the early 1990s and was followed by a sharp decline from 1992 to 1995 during which incidence rates returned to a new baseline, likely due to the fact that increased screening in prior years had successfully diagnosed much of the previously undetected prostate cancer patients in the population.
Gender Differences: Implications for Clinical Trials and Practice
  • A. CeribelliM. PinoF. Cecere
  • Medicine
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2007
There is considerable controversy over the relative risk for lung cancer among women versus men at any given level of tobacco exposure, and multiple studies suggest that women may be more susceptible than men to the carcinogenic effects of cigarette smoke as a result of genetic, metabolic, and hormonal factors.
Trends in lung cancer mortality in South Africa: 1995-2006
The more recent declining lung cancer mortality rate in men is welcome but the increasing rate in women is a public health concern that warrants intervention.
Cancer Incidence Among Children and Adolescents in the United States, 2001–2003
This study is the first to demonstrate substantial regional differences in the incidence of childhood cancer, and shows that incidence varies according to gender, age, race, ethnicity, and geography.
The worldwide epidemiology of prostate cancer: perspectives from autopsy studies.
The prevalence of prostate cancer must be established to predict the expected incidence of the disease and in order to plan rational detection and treatment strategies, improved cancer registration is needed in developing nations.
Survival and degree of spread for female breast cancers in New South Wales from 1980 to 2003: implications for cancer control
Case fatalities from breast cancer have declined by diagnostic period, after adjusting for degree of spread, which may reflect treatment and screening advances, and attention should be directed at reducing disparities by socio-economic status and encouraging migrant women to present earlier.
A New Method of Estimating United States and State‐level Cancer Incidence Counts for the Current Calendar Year
A new method is presented that uses statistical models of cancer incidence that incorporate potential predictors of spatial and temporal variation of cancer occurrence and that account for delay in case reporting and then projects these estimated numbers of cases ahead 4 years using a piecewise linear (joinpoint) regression method.


Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment.
Cancer death rates for all cancer sites combined and for many common cancers have declined at the same time as the dissemination of guideline-based treatment into the community has increased, although this progress is not shared equally across all racial and ethnic populations.
Trends in Breast Cancer by Race and Ethnicity
Trends in incidence, mortality, and survival rates of female breast cancer in the United States by race and ethnicity are described and continued efforts are needed to increase the availability of high‐quality mammography and treatment to all segments of the population.
A New Method of Predicting US and State‐Level Cancer Mortality Counts for the Current Calendar Year
The improved accuracy of the new method was particularly evident for prostate cancer, for which mortality rates changed dramatically in the late 1980s and early 1990s.
Impact of reporting delay and reporting error on cancer incidence rates and trends.
Investigating the impact of reporting delay and reporting error on incidence rates and trends for cancers of the female breast, colorectal, lung/bronchus, prostate, and melanoma found reporting-adjusted cancer incidence rates are valuable in precisely determining current cancer incidence levels and trends and in monitoring the timeliness of data collection.
Cancer Disparities by Race/Ethnicity and Socioeconomic Status
Differences in cancer incidence, mortality, and survival in relation to race/ethnicity, and census data on poverty in the county or census tract of residence are highlighted.
Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study.
This study describes racial or ethnic patterns of cancer-specific survival and relative risks of cancer death for all cancers combined and for cancers of the colon and rectum, lung and bronchus, prostate, and female breast for the 6 major USracial or ethnic groups.
Survival of blacks and whites after a cancer diagnosis.
Only modest cancer-specific survival differences are evident for blacks and whites treated comparably for similar-stage cancer, suggesting differences in cancer biology between racial groups are unlikely to be responsible for a substantial portion of the survival discrepancy.
Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results.
Both the median OS and 5-year survival rates seem to be improved with adjuvant RAIT after complete LM resection in CRC, compared with historical and contemporaneous controls not receiving RAIT, which justifies further evaluation of this modality in a multicenter, randomized trial.
Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer.
  • Shaoliang ChenLi-ke Yu D. Ju
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
Radioimmunotherapy with (131)I-chTNT was well tolerated and can be used systemically or locally to treat refractory tumors of the lung.
Radioimmunotherapy of the GW-39 human colonic tumor xenograft with 131I-labeled murine monoclonal antibody to carcinoembryonic antigen.
The results confirm the previous studies that 131I-labeled antibody can effectively inhibit tumor growth, but suggest that radioantibody therapy is most effectively administered when there is a low tumor burden.